IGXT (MC $48 M) FDA DECISION ON FEBRUARY 3 =500%+ Potential !!!

[Biotechmaster]

IGXT is one of the Best and Most Undervalued Gem in the Biotech Sector . Market Cap of $48 M for a Company with10 Drugs in Late Stage which all could be on the Market within 3 years is more than Ridiculous .

2 Big Drugs already under review by FDA another 1 NDA filing for "Best in Class" Potency Drug and 1 ANDA filing for CHF will follow within 6 months .

NDA submission for our anti-migraine VersaFilm(TM) product had been accepted for review, with an FDA-assigned PDUFA date of February 3, 2014.
(According to Merck's most recent annual report, sales of Maxalt(R) were $638 million in 2012.)

IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
(According to IMS Health, U.S. retail sales of Suboxone(R) Sublingual Film were approximately $1.5 billion in 2012.)

Only 35 M on the float ..IGXT has the Potential to hit $10++ within 2 Year ! GLTA

Intelgenx (IGXT)

Market Cap : $48 M
Cash: $6 M
Price:0.70

Burn-Rate : $2 M a year
Shares Out : 69 M ( 31 M shares are held by Investors )


Mega Product Pipeline



New Presentation



Here is a Summary from he largest Shareholder of IGXT (he sees Tgt of $5-10) !!!

Frankly, my target (first stated in July, 2011) of realizing $3-$8/share from IntelGenx over the
life of the BIPES Fund has never seemed more reason able